To my knowledge, none of the costs of phase iii and upcoming trials have been outlaid yet, so even though they have raised a decent amount, and the attached rebates. They will have tens of millions coupled with the 8mil a year running costs to pay in the forseeable future. They may indeed need another raise before getting any meaningful results. On the positive, one would assume indo would be much cheaper.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
-0.010(3.17%) |
Mkt cap ! $87.95M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.0¢ | 30.0¢ | $25.09K | 82.18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 32855 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 16280 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |